White label ELPA - ClinicalTrials.eu

Study on the Effectiveness of Autologous Bone Marrow Cells for Patients with Dilated Cardiomyopathy and Heart Failure

Not recruiting

2 1
Investigated Diseases:
- Cardiomyopathy
- Dilated cardiomyopathy
Investigated Drugs:
- Autologous Bone Marrow-Derived Adult Mononuclear Cells, Not Expanded
Study Comparing Sotorasib and Panitumumab with Other Drug Combinations for Patients with Metastatic Colorectal Cancer and KRAS p.G12C Mutation

Not recruiting

3 1 1 1
Investigated Drugs:
Study on the Safety and Tolerability of Leriglitazone for Children with Rett Syndrome

Not recruiting

2 1
Investigated Drugs:
- Leriglitazone
Study on the Effects of Landiolol Hydrochloride for Patients with Microcirculatory Issues During Septic Shock

Not recruiting

3 1 1 1
Investigated Drugs:
- Landiolol Hydrochloride
Study on the Safety and Effects of PDC*lung01 Vaccine with Pemetrexed or Pembrolizumab for Patients with Non-Small Cell Lung Cancer

Not recruiting

2 1 1 1
Investigated Diseases:
- Non-small cell lung cancer
Investigated Drugs:
Title: Comparing Brentuximab Vedotin plus ESHAP versus ESHAP alone in treating patients with relapsed or refractory classical Hodgkin’s Lymphoma

Not recruiting

2 1 1 1
Investigated Diseases:
- Hodgkin’s disease
Investigated Drugs:
- Brentuximab Vedotin
Study of tovorafenib versus standard chemotherapy as first treatment for children with low-grade glioma with RAF gene changes

Not recruiting

3 1 1 1
Investigated Diseases:
- Malignant glioma
Investigated Drugs:
+10
Study on Atezolizumab for Patients with Locally Advanced Cervical Cancer

Not recruiting

2 1 1 1
Investigated Diseases:
- Cervix carcinoma
Investigated Drugs:
- Atezolizumab
Study of Elraglusib Alone or with Chemotherapy for Patients with Refractory Blood Cancers or Solid Tumors

Not recruiting

2 1 1 1
Investigated Drugs:
Study on Pembrolizumab and Eftilagimod Alfa with Radiotherapy for Patients with Resectable Soft Tissue Sarcomas

Not recruiting

2 1 1 1
Investigated Drugs:
- Eftilagimod Alfa
- Pembrolizumab

Full Name *

e-Mail *

Country Prefix *

Phone Number *

Nationality *

Gender *

Check all consents

Check all consents

I accept the Terms and Conditions and Privacy Policy *

*I accept the Terms and Conditions and Privacy Policy

I consent to receiving commercial information from the Service Operator *

*I consent to receiving commercial information from the Service Operator

I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes *

*I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes

We use cookies